ConjuChem Company

ConjuChem creates novel, next-generation medicines using unique, long-acting therapeutic peptides. Underlying all ConjuChem compounds are bioconjugation platforms called Drug Affinity Complex (DAC™) and Preformed Conjugate-Drug Affinity Complex (PC-DAC™). When applied to a given peptide, DAC™ and PC- DAC™ can create new drugs with similar therapeutic activities but with significantly longer durations of activity and improved safety profiles.
Technology: Metabolic Disorders
Industry: Metabolism Dysfunctions
Headquarters: United States
Founded Date: 1997
Employees Number: 11-50
Estimated Revenue: Less than $1M

Visit Website
JHodson@aaah.com
Register and Claim Ownership